海外の治験の状況「1」での検索結果
224件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 地域
- 登録日
Authorised
- NA
- Gaucher disease MedDRA version: 14.0 Level: PT Classification code 10018048 Term: Gaucher's disease System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
- Canada, Chile, Israel, Italy, Mexico, Serbia, South Africa, Spain
- 2011-10-13
Authorised
- PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive/HER2-negative early breast cancer
- To determine whether the addition of palbociclib to adjuvant endocrine therapy will improve outcomes over endocrine therapy alone for HR+/HER2- early breast cancer. MedDRA version: 20.1 Level: LLT Classification code 10070575 Term: Estrogen receptor positive breast cancer System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Austria, Belgium, Canada, Germany, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic of, Mexico, Netherlands, Poland, Portugal, Spain, Sweden, Switzerland, Taiwan, United Kingdom, United States
- 2015-06-11
Authorised
- A Study Of Taselisib + Fulvestrant Versus Placebo + Fulvestrant In Patients With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression during or After Aromatase Inhibitor Therapy
- WOMEN WITH ER-POSITIVE AND HER2-NEGATIVE, LOCALLY ADVANCED OR METASTATIC BREAST CANCER WHO HAS DIDEASE RECURRENCE OR PROGRESSION DURING OR AFTER AROMATASE INHIBITOR THERAPY MedDRA version: 17.1 Level: LLT Classification code 10070575 Term: Estrogen receptor positive breast cancer System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Austria, Bulgaria, Canada, Colombia, Czech Republic, France, Germany, Greece, Italy, Japan, Korea, Republic of, Mexico, Netherlands, Peru, Poland, Portugal, Romania, Russian Federation, Spain, Sweden, Turkey, United States
- 2015-01-12
Authorised
- Long term continuous infusion ch14.18/CHO plus s.c. aldesleukin (IL-2) randomised
- High-risk neuroblastoma patients having received at least one previous high dose treatment followed by stem cell rescue after conventional therapy fulfilling one of the following criteria: • Primary refractory patients with stage 4 disease with at least two lines of treatment prior to HDT/SCT, causing a delay from diagnosis to SCT of over 9 months • Relapse after primary stage 4 disease • Disseminated relapse after primary localized neuroblastoma ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Austria, Belgium, France, Germany, Hong Kong, Ireland, Israel, Italy, Poland, Spain, United Kingdom
- 2010-09-24
Authorised
- A study evaluating efficacy of the drug BGB-290 in patients with gastric cancer that responded to previous chemotherapy.
- Inoperable Locally Advanced or Metastatic Gastric Cancer that Responded to Platinum-based First-line Chemotherapy MedDRA version: 20.0 Level: PT Classification code 10063916 Term: Metastatic gastric cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Belgium, China, France, Germany, Hong Kong, Hungary, Italy, Japan, Poland, Russian Federation, Singapore, Spain, Taiwan, United Kingdom, United States
- 2018-01-17
Authorised
- A Phase 2 clinical study evaluating safety and efficacy of EDP-305 in Subjects with Primary Biliary Cholangitis (PBC) without adequate response or intolerance to Ursodeoxycholic Acid (UDCA).
- Primary Biliary Cholangitis (PBC) MedDRA version: 20.1 Level: LLT Classification code 10036680 Term: Primary biliary cirrhosis System Organ Class: 100000004871 ;Therapeutic area: Body processes [G] - Immune system processes [G12]
- Australia, Austria, Belgium, Canada, France, Germany, Netherlands, Spain, United Kingdom, United States
- 2018-05-24
Authorised
- A Phase 2 clinical study evaluating safety and efficacy of EDP-305 in Subjects with Primary Biliary Cholangitis (PBC) without adequate response or intolerance to Ursodeoxycholic Acid (UDCA).
- Primary Biliary Cholangitis (PBC) MedDRA version: 20.1 Level: LLT Classification code 10036680 Term: Primary biliary cirrhosis System Organ Class: 100000004871 ;Therapeutic area: Body processes [G] - Immune system processes [G12]
- Australia, Austria, Belgium, Canada, France, Germany, Netherlands, Spain, United Kingdom, United States
- 2018-05-16
Authorised
- A Study with an active treatment to Assess the Long-term Safety of Weekly Intravenous Product in Subjects with Pulmonary Emphysema due to Alpha1-Antitrypsin Deficiency
- Pulmonary Emphysema due to Alpha-1-Antitrypsin Deficiency MedDRA version: 20.0 Level: LLT Classification code 10014563 Term: Emphysema pulmonary System Organ Class: 100000004855 ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
- Australia, Canada, Denmark, Estonia, New Zealand, Poland, Sweden, United States
- 2018-02-16
Authorised
- A Study with an active treatment to Assess the Long-term Safety of Weekly Intravenous Product in Subjects with Pulmonary Emphysema due to Alpha1-Antitrypsin Deficiency
- Pulmonary Emphysema due to Alpha-1-Antitrypsin Deficiency MedDRA version: 19.0 Level: LLT Classification code 10014563 Term: Emphysema pulmonary System Organ Class: 100000004855 ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
- Argentina, Australia, Brazil, Canada, Denmark, Estonia, France, Germany, New Zealand, Poland, Romania, Russian Federation, Spain, Sweden, United States
- 2016-01-29
Authorised
- A study to evaluate the drug Mongersen (GED-0301) for the treatment of Crohn’s disease
- Active Crohn's disease MedDRA version: 20.0 Level: LLT Classification code 10021315 Term: Ileitis terminal System Organ Class: 100000016693 ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
- Australia, Austria, Belgium, Bulgaria, Canada, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Israel, Italy, Korea, Republic of, Latvia, Netherlands, New Zealand, Norway, Poland, Portugal, Romania, Russian Federation, Serbia, Slovakia, South Africa, Spain, Sweden, Switzerland, Turkey, Ukraine, United Kingdom, United States
- 2015-11-18